Table 2.

Efficacy analysis (primary endpoint).

Combination	No. (%)	Maintenance	No. (%)
Best response		Best response
n	55		55
CR	9 (16.4%)	CR	19 (34.5%)
CRu	3 (5.5%)	CRu	4 (7.3%)
PR	33 (60.0%)	PR	25 (45.5%)
SD	5 (9.1%)	SD	3 (5.5%)
PD	4 (7.3%)	PD	4 (7.3%)
Not assessed	1 (1.8%)
Overall response		Overall response
n	55
OR	45 (81.8%)	OR	48 (87.3%)

Reported separately at the end of the combination therapy with bortezomib and ibrutinib (left), and during the maintenance with ibrutinib (maintenance, right).

CR, complete remission; CRu, complete remission unconfirmed; PR, partial remission; SD, stable disease; PD, progressive disease. Response according to Cheson, 1999.¹²